Segment Reporting

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Segment Reporting

7.   Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management ("CRM"), electrophysiology ("EP"), critical care, interventional oncology and spine devices, and our Cianna Medical product line. Our endoscopy segment focuses on the gastroenterology, pulmonary and thoracic surgery specialties, with a portfolio consisting primarily of stents, dilation balloons, certain inflation devices, guide wires, and other disposable products. We evaluate the performance of our operating segments based on net sales and operating income.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and nine-month periods ended September 30, 2019 and 2018, were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Net Sales
Cardiovascular	$	234,426	$	212,150	$	711,570	$	624,392
Endoscopy		8,623		9,509		25,360		25,112
Total net sales		243,049		221,659		736,930		649,504
Operating Income (Loss)
Cardiovascular		(6,210)		18,199		11,263		37,263
Endoscopy		3,329		2,862		7,581		7,692
Total operating income (loss)		(2,881)		21,061		18,844		44,955
Total other expense - net		(2,809)		(1,676)		(8,689)		(7,646)
Income tax expense (benefit)		(2,292)		2,766		499		4,481
Net income (loss)	$	(3,398)	$	16,619	$	9,656	$	32,828